Question · Q3 2025
Li Wenwen asked about Viatris's confidence in the sales ramp and peak sales potential for fast-acting meloxicam, and if there were any lessons learned from competitor JornoVix's slow launch.
Answer
CEO Scott Smith expressed strong excitement for meloxicam, citing data and team expertise, estimating peak sales in the $500 million range, with more clarity in 2026. He emphasized plans to commercialize it as a branded product, expecting it to be a meaningful contributor for at least the rest of the decade, with active efforts to expand its IP and exclusivity.